News
Events
US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy
May 16, 2022STOCKHOLM, SWEDEN, - May 16, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled - "Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study" and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor, Dermatology Department, et al at Icahn School of Medicine at Mount Sinai, New York, was published online in "SKIN-The Journal of Cutaneous medicine".
Interim Report Q1 2022
May 12, 2022January 1 - March 31, 2022
SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022
May 10, 2022SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will present an update on the latest developments from SciBase at the Redeye Medtech & Diagnostics seminar on May 11th at 10.55 pm. The presentation will be followed by a short Q&A. The presentations are live broadcasted at https://www.redeye.se/events/825143/redeye-theme-medtech-diagnostics . The presentation will also be available at www.redeye.se and on the Company's website i n Redeye Universe.
- Load more news...